- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00737243
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients With Carcinoma of Unknown Primary Site
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Huntsville, Alabama, United States, 35805
- Oncology Specialties (Clearview Cancer Institute)
-
-
Florida
-
Fort Myers, Florida, United States, 33901
- Florida Cancer Specialists
-
Jacksonville, Florida, United States, 32256
- Integrated Community Oncology Network
-
Lakeland, Florida, United States, 33805
- Watson Clinic Center for Cancer Care and Research
-
Orlando, Florida, United States, 32804
- Florida Hospital Cancer Institute
-
-
Georgia
-
Gainesville, Georgia, United States, 30501
- Northeast Georgia Medical Center
-
Marietta, Georgia, United States, 30060
- Wellstar Cancer Research
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- Oncology Hematology Associates of SW Indiana
-
-
Kentucky
-
Louisville, Kentucky, United States, 40207
- Baptist Hospital East
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Hematology Oncology Clinic, LLP
-
-
Maryland
-
Bethesda, Maryland, United States, 20817
- Center for Cancer and Blood Disorders
-
-
Michigan
-
Grand Rapids, Michigan, United States, 49503
- Grand Rapids Clinical Oncology Program
-
-
Mississippi
-
Jackson, Mississippi, United States, 39202
- Jackson Oncology Associates
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Nebraska Methodist Cancer Center
-
-
New Jersey
-
Morristown, New Jersey, United States, 07960
- Hematology Oncology Associates of Northern NJ
-
-
Ohio
-
Cincinnati, Ohio, United States, 45242
- Oncology Hematology Care
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29303
- Spartanburg Regional Medical Center
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37404
- Chattanooga Oncology Hematology Associates
-
Nashville, Tennessee, United States, 37023
- Tennessee Oncology, PLLC
-
-
Texas
-
Ft. Worth, Texas, United States, 76104
- Center for Cancer and Blood Disorders
-
-
Virginia
-
Richmond, Virginia, United States, 23235
- Virginia Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients must have carcinoma of unknown primary site after the following diagnostic procedures have been performed and are unrevealing of a primary site:
- Complete medical history and physical examination,
- Complete blood counts, chemistry profile,
- CT scans of the chest and abdomen,
- Directed evaluation of any symptomatic areas,
- PET scan (recommended).
Patients must have biopsy-proven metastatic carcinoma, with any of the following light microscopic histologies:
- Adenocarcinoma,
- Poorly differentiated adenocarcinoma,
- Poorly differentiated carcinoma (all patients with poorly differentiated carcinoma must have immunoperoxidase stains to rule out other treatable malignancies [e.g., lymphoma, neuroendocrine carcinoma]),
- Poorly differentiated squamous carcinoma.
- Patients must have biopsy material available from a surgical biopsy, a core needle biopsy, or a fine needle aspiration biopsy to provide an adequate specimen (must be 40% tumor) for the molecular profiling assay.
- An ECOG performance status 0, 1, or 2.
- No previous treatment with any systemic therapy.
- Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST).
Laboratory values as follows:
- WBC 4000/micro L,
- Platelets 100,000/micro L,
- Serum bilirubin <1.5 times the institutional upper limits of normal (ULN),
- Serum creatinine < 2.0 mg/dL.
- Patients with brain metastases are eligible only if all lesions have been controlled by surgical resection or radiation therapy, the patient is not steroid-dependent, and the patient meets all other eligibility criteria.
- Patients must be > 4 weeks from any major operative procedure.
- To be eligible for the TREATMENT portion of the study, patients must have one of the five following diagnoses: colorectal, pancreas, NSCLC, ovary, renal cancer.
- Patients must be able to understand the nature of this study and give written informed consent.
Exclusion Criteria:
Patients with the following specific syndromes are not eligible:
- Patients with neuroendocrine carcinoma,
- Women with adenocarcinoma isolated to axillary lymph nodes,
- Women with adenocarcinoma isolated to peritoneal involvement,
- Patients with carcinoma involving only 1 site, with resectable tumor at that site, or
- Patients with squamous carcinoma limited to cervical, supraclavicular, or inguinal lymph nodes.
- Patients with uncontrolled brain metastases and all patients with meningeal metastases.
- Patients with insufficient biopsy material available for molecular profiling assay.
- Women who are pregnant or lactating. All females of child-bearing potential must have a negative serum or urine pregnancy tests within 7 days prior to study treatment.
- Men and women of childbearing potential are required to use effective methods of contraception during this study and for 6 months after ending therapy.
- Patients who have received any other experimental drug within 28 days of starting treatment.
Exclusion Criteria for All Patients Receiving Bevacizumab-Containing Regimens
- Patients with history of acute myocardial infarction within 6 months, other clinically significant cardiovascular disease (e.g., unstable angina, New York Heart Association [NYHA] grade 2 congestive heart failure [CHF], serious cardiac arrhythmias requiring medication) or > grade 2 vascular disease.
- Patients with uncontrolled hypertension (systolic blood pressure [BP] 150 or diastolic BP >100mm Hg) or uncontrolled cardiac arrhythmias.
- Prior hypertensive crisis or hypertensive encephalopathy.
Patients with clinical history of hemoptysis (defined as bright red blood of
½ teaspoon per episode) or hematemesis within 1 month prior to Day 1.
- Patients with PEG tubes or G tubes.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study.
- Core biopsy or other minor surgical procedure excluding placement of a vascular access device, within 7 days prior to Day 1.
- Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1.
- Patients with proteinuria (1000 mg/24 hours) at screening will be excluded. A 24-hour urine collection is not required in all patients (e.g., patients whose treatment plans exclude bevacizumab); however, all patients receiving bevacizumab with 1+ proteinuria on dipstick urinalysis at study entry must have a subsequent 24-hour urine collection.
- Patients with any non-healing wound, ulcer, or long bone fracture.
- Patients with any history of a bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
- Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.
- Patients with a history of stroke or transient ischemic attach within 6 months prior to first bevacizumab dose.
- Known hypersensitivity to any component of bevacizumab.
- Patients with history of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a novel regimen, or that might affect the results of this study or render the subject at high risk for treatment complications.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
|
175 mg/m2, 1-3 hour IV infusion Day 1
AUC 6.0 IV Day 1
15 mg/kg IV infusion Day 1
Other Names:
150 mg PO
Other Names:
|
OTHER: Treatment determined by physician
Other treatment determined by physician based on molecular profiling assay
|
15 mg/kg IV infusion Day 1
Other Names:
150 mg PO
Other Names:
Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: every 6-8 weeks (2 cycles) until death from any cause or lost to follow up, projected 18 months
|
Defined as the elapsed time from the start of treatment to the date of death from any cause or lost to follow-up.
Participants lost to follow up were censored as of the last date known to be alive.
|
every 6-8 weeks (2 cycles) until death from any cause or lost to follow up, projected 18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With a Tissue of Origin Successfully Predicted by the Assay
Time Frame: at baseline
|
To evaluate the utility of the assay in identifying the tissue of origin in patients with carcinoma of unknown primary site (CUP), an archived tumor specimen was assayed upon study entry.
If a tissue of origin was predicted by the assay, participants received standard site-specific therapy for that tumor type.
When tissue of origin was not predicted by the assay, patients received standard empiric chemotherapy for CUP and were not followed further.
If the assay was not completed due to inadequate amount of tumor in the biopsy specimen, patients were not treated on the study.
|
at baseline
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Glandular and Epithelial
- Carcinoma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Carboplatin
- Paclitaxel
- Erlotinib Hydrochloride
- Bevacizumab
Other Study ID Numbers
- SCRI UNKPRI 20
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma
-
Eye & ENT Hospital of Fudan UniversityChanghai Hospital; Fudan University; RenJi Hospital; Xinhua Hospital, Shanghai... and other collaboratorsRecruitingGlottic Carcinoma | Supraglottic Carcinoma | Subglottic Carcinoma | Pyriform Sinus Carcinoma | Postcricoid Carcinoma | Posterior Pharyngeal Wall CarcinomaChina
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditionsUnited States
-
National Cancer Institute (NCI)Not yet recruitingBreast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.WithdrawnMetastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Unresectable Renal Pelvis Urothelial Carcinoma | Unresectable Ureter Urothelial CarcinomaUnited States
-
Ohio State University Comprehensive Cancer CenterEmbr Labs, Inc.Active, not recruitingHot Flashes | Breast Carcinoma | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In SituUnited States
-
Institut BergoniéCompletedIntraductal Carcinoma and Lobular Carcinoma in SituFrance
-
University of UtahNational Cancer Institute (NCI)RecruitingMetastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid VariantUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Laryngeal Verrucous Carcinoma | Recurrent Oral Cavity Verrucous Carcinoma | Tongue... and other conditionsUnited States
Clinical Trials on Paclitaxel
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast CarcinomaUnited States
-
Anne NoonanNational Cancer Institute (NCI)RecruitingStage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic AdenocarcinomaUnited States
-
Hutchison Medipharma LimitedSun Yat-sen UniversityActive, not recruitingAdvanced Gastric CancerChina
-
University of WashingtonNational Cancer Institute (NCI); Celgene CorporationCompletedRecurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung CancerUnited States
-
Shengjing HospitalRecruiting
-
CTI BioPharmaTerminatedNSCLCUnited States, Canada, Bulgaria, Romania, Russian Federation, Ukraine, Mexico, Argentina, Hungary, Poland, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
CTI BioPharmaTerminated
-
Novartis PharmaceuticalsCompletedMetastatic or Locally Advanced Solid TumorsNetherlands, Spain, Germany, Switzerland, Belgium